MTEM

Molecular Templates, Inc. [MTEM] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

MTEM Stock Summary

Top 10 Correlated ETFs

MTEM


Top 10 Correlated Stocks

MTEM


In the News

05:55 28 Mar 2024 MTEM

Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.

04:12 28 Mar 2024 MTEM

Molecular Templates to Participate in Upcoming Investor Conferences

AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced participation in the following upcoming investor conferences:

10:31 28 Mar 2024 MTEM

Looking for a Fast-paced Momentum Stock at a Bargain? Consider Molecular Templates Inc. (MTEM)

Molecular Templates Inc. (MTEM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

05:10 28 Mar 2024 MTEM

Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, announced today the presentation of a poster at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. One-on-one meetings may be scheduled directly with Molecular Templates.

11:48 28 Mar 2024 MTEM

9 Hot Penny Stocks Under $0.99 To Watch Right Now

Penny stocks to watch under $1 The post 9 Hot Penny Stocks Under $0.99 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

09:40 28 Mar 2024 MTEM

Molecular Templates Inc. (MTEM) Reports Q4 Loss, Lags Revenue Estimates

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -56% and 63.99%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

08:01 28 Mar 2024 MTEM

Why Is Molecular Templates (MTEM) Stock Up 36% Today?

Molecular Templates (NASDAQ: MTEM ) stock is rocketing higher on Friday after the company got approval from the FDA. That FDA approval has to do with its IND application for its cancer treatment.

04:44 28 Mar 2024 MTEM

Molecular Templates Announces Participation in Upcoming Conferences

AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, announced participation in the following upcoming 2023 conferences:

05:02 28 Mar 2024 MTEM

Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that they will present a poster on interim clinical results for the MT-5111 program at the San Antonio Breast Cancer Symposium (SABCS) which will take place December 6 – December 10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX. Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 – December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA. In-person and virtual meetings may be scheduled directly with Molecular Templates.

04:30 28 Mar 2024 MTEM

Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI's 5th Annual HealthCONx Conference and Piper Sandler's 34th Annual Healthcare Conference

AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that CEO, Eric Poma, Ph.D., will present a virtual fireside chat at Evercore ISI's 5th Annual HealthCONx conference which will take place November 29 – December 1, 2022, and an in-person fireside chat with an analyst Q&A portion at Piper Sandler's 34th Annual Healthcare Conference in New York, NY which will take place November 29 – December 1, 2022. Highlighting positive incremental data, the chats will comprise a review of the de-immunized next-generation ETB scaffold and programs. One-on-one meetings may be scheduled with banking representatives of Evercore ISI or Piper Sandler, respectively, or directly with Molecular Templates.

MTEM Financial details

Company Rating
Strong Buy
Market Cap
9.94M
Income
-20.25M
Revenue
49.66M
Book val./share
1.34
Cash/share
3.1
Dividend
-
Dividend %
-
Employees
111
Optionable
No
Shortable
Yes
Earnings
28 Mar 2024
P/E
-0.94
Forward P/E
-0.79
PEG
-0.15
P/S
0.41
P/B
2.81
P/C
0.72
P/FCF
-0.36
Quick Ratio
0.73
Current Ratio
1.06
Debt / Equity
1.88
LT Debt / Equity
1.53
-
-
EPS (TTM)
-2.31
EPS next Y
-2.85
EPS next Q
1.57
EPS this Y
15.38%
EPS next Y
23.38%
EPS next 5Y
1672.73%
EPS last 5Y
-35.99%
Revenue last 5Y
22.09%
Revenue Q/Q
2.55%
EPS Q/Q
-128.37%
-
-
-
-
SMA20
-50%
SMA50
-50%
SMA100
-60%
Inst Own
42.68%
Inst Trans
0.98%
ROA
-46%
ROE
428%
ROC
-0.7%
Gross Margin
35%
Oper. Margin
-32%
Profit Margin
-41%
Payout
-
Shs Outstand
5.37M
Shs Float
4.42M
-
-
-
-
Target Price
-
52W Range
1.68-9.45
52W High
-75.11%
52W Low
+124%
RSI
38
Rel Volume
26.64
Avg Volume
13.62K
Volume
362.67K
Perf Week
27.27%
Perf Month
-38.12%
Perf Quarter
-67.35%
Perf Half Y
-64.04%
-
-
-
-
Beta
1.201
-
-
Volatility
0.23%, 0.81%
Prev Close
-5.08%
Price
2.24
Change
-8.2%

MTEM Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
3.690.520.330.70.35
Net income per share
-15.35-1.84-2.2-1.43-1.65
Operating cash flow per share
-2.26-0.67-1.76-0.55-1.58
Free cash flow per share
-5.16-0.92-1.92-0.62-1.64
Cash per share
49.643.311.972.591.08
Book value per share
51.132.731.251.19-0.27
Tangible book value per share
37.642.691.221.17-0.28
Share holders equity per share
51.132.731.251.19-0.27
Interest debt per share
4.870.810.650.920.98
Market cap
119.59M7.93B6.7B3.25B278.86M
Enterprise value
35.12M7.86B6.71B3.27B297.25M
P/E ratio
-3.95-113.98-63.91-41-3.01
Price to sales ratio
16.42406.49428.8484.0214.12
POCF ratio
-26.78-313.98-80.01-107-3.13
PFCF ratio
-11.74-227.15-73.53-94.57-3.02
P/B Ratio
1.1976.93112.9949.52-18.43
PTB ratio
1.1976.93112.9949.52-18.43
EV to sales
4.82402.86428.9684.5415.05
Enterprise value over EBITDA
-1.16-170.76-67.19-40.86-3.38
EV to operating cash flow
-7.87-311.17-80.04-107.66-3.34
EV to free cash flow
-3.45-225.12-73.55-95.15-3.22
Earnings yield
-0.25-0.01-0.02-0.02-0.33
Free cash flow yield
-0.090-0.01-0.01-0.33
Debt to equity
0.090.280.490.73-3.34
Debt to assets
0.060.170.210.250.52
Net debt to EBITDA
2.791.54-0.02-0.25-0.21
Current ratio
3.233.912.73.181.2
Interest coverage
-31.31-54.28-59.14-23.77-18.58
Income quality
0.150.360.80.370.96
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.931.031.710.881.33
Research and developement to revenue
4.152.595.952.194.17
Intangibles to total assets
0.190.010.010.010.01
Capex to operating cash flow
1.280.380.090.130.04
Capex to revenue
-0.79-0.49-0.47-0.1-0.16
Capex to depreciation
-5.87-8.16-1.89-0.6-0.43
Stock based compensation to revenue
0.550.30.760.430.6
Graham number
132.8810.637.866.193.15
ROIC
-0.3-0.49-1-0.62-1.86
Return on tangible assets
-0.27-0.4-0.76-0.41-0.96
Graham Net
30.411.670.350.3-0.92
Working capital
72.35M104.1M63.77M101.55M11.22M
Tangible asset value
74.28M101.73M58.14M64.56M-15.83M
Net current asset value
65.61M68.73M20.79M21.52M-44.38M
Invested capital
0.090.280.490.73-3.34
Average receivables
120K3.87M3.87M117K0
Average payables
1.65M1.12M1.91M1.98M1.06M
Average inventory
1.12M4.53M6.45M3.04M0
Days sales outstanding
12.03140.545.4600
Days payables outstanding
9.4310.589.2387.8223.58
Days of inventory on hand
27.1249.2623.8700
Receivables turnover
30.352.666.8200
Payables turnover
38.7234.4839.564.1615.48
Inventory turnover
13.467.4115.2900
ROE
-0.3-0.67-1.77-1.216.13
Capex per share
-2.9-0.26-0.16-0.07-0.06

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.080.050.61.761.33
Net income per share
-0.44-0.390.15-2.890.82
Operating cash flow per share
-0.43-0.33-0.34-2.57-1.48
Free cash flow per share
-0.45-0.33-0.35-2.57-1.48
Cash per share
1.411.080.741.323.1
Book value per share
0.07-0.27-0.03-2.311.34
Tangible book value per share
0.07-0.28-0.03-2.311.34
Share holders equity per share
0.07-0.27-0.03-2.311.34
Interest debt per share
0.920.920.923.882.51
Market cap
633.95M278.94M321.2M27.05M32.19M
Enterprise value
661.99M297.33M330.46M35.47M29.19M
P/E ratio
-6.43-3.169.44-0.621.94
Price to sales ratio
149.52106.839.554.084.74
POCF ratio
-25.95-15.13-16.59-2.81-4.27
PFCF ratio
-24.95-14.88-16.43-2.8-4.27
P/B Ratio
152.68-18.43-168.17-3.124.73
PTB ratio
152.68-18.43-168.17-3.124.73
EV to sales
156.13113.889.835.354.29
Enterprise value over EBITDA
-30.73-14.4127-3.795.68
EV to operating cash flow
-27.1-16.13-17.07-3.68-3.87
EV to free cash flow
-26.05-15.86-16.91-3.67-3.87
Earnings yield
-0.04-0.080.03-0.40.13
Free cash flow yield
-0.04-0.07-0.06-0.36-0.23
Debt to equity
12.12-3.34-26.35-1.541.88
Debt to assets
0.420.520.640.380.29
Net debt to EBITDA
-1.3-0.890.76-0.9-0.58
Current ratio
1.741.21.730.441.06
Interest coverage
-18.9-15.178.45-9.88-165.71
Income quality
0.990.84-1.790.891.81
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.42.330.170.780.63
Research and developement to revenue
5.186.740.572.020.84
Intangibles to total assets
00.01000
Capex to operating cash flow
0.040.020.0100
Capex to revenue
-0.23-0.12-0.0100
Capex to depreciation
-0.54-0.17-0.09-0.010
Stock based compensation to revenue
0.6210.070.270.18
Graham number
0.851.540.3412.264.95
ROIC
-0.34-0.440.15-0.720.22
Return on tangible assets
-0.21-0.230.11-0.310.09
Graham Net
-0.62-0.92-0.63-9.87-4.21
Working capital
36.96M11.22M21.72M-15.11M1.19M
Tangible asset value
4.15M-15.83M-1.91M-8.68M6.8M
Net current asset value
-27.31M-44.38M-28.79M-32.37M-14.56M
Invested capital
12.12-3.34-26.35-1.541.88
Average receivables
001.42M1.56M137K
Average payables
1.36M794.5K1.61M3.69M3.63M
Average inventory
001M2.95M1.94M
Days sales outstanding
007.63.720
Days payables outstanding
48.8321.612.8531.33154.98
Days of inventory on hand
009.526.080
Receivables turnover
0011.8524.190
Payables turnover
1.844.177.012.870.58
Inventory turnover
009.483.450
ROE
-5.931.46-4.461.250.61
Capex per share
-0.02-0.01000

MTEM Frequently Asked Questions

What is Molecular Templates, Inc. stock symbol ?

Molecular Templates, Inc. is a US stock , located in Austin of Tx and trading under the symbol MTEM

What is Molecular Templates, Inc. stock quote today ?

Molecular Templates, Inc. stock price is $2.24 today.

Is Molecular Templates, Inc. stock public?

Yes, Molecular Templates, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap